Nasdaq IPOs

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, announced terms for its IPO on Friday. The Houston, TX-based company plans to raise $25 million by offering 1.9 million shares at a price range of $12 to $14. At the midpoint o

Presidio Property Trust, a diversified REIT repositioning its portfolio to focus on office and industrial properties, raised the proposed deal size for its upcoming IPO on Friday. In its latest filing, the company also removed Aegis Capital as an underwriter and added Kingsw

ACell, which makes medical devices for wounds and soft tissue surgical defects, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company's urinary bladder matrix (UBM) product is designed to help manage the healing and scarring of traumat

Malacca Straits Acquisition, a blank check company targeting a businesses in Southeast Asia, filed on Friday with the SEC to raise up to $125 million in an initial public offering. The Hong Kong-based company plans to raise $125 million by offering 12.5 million units at $10. Each

PCI Media, a producer of animated television commercials and other media, withdrew its plans for an initial public offering on Friday. It originally filed in January 2019 and set terms the following June to raise $18 million by offering 2.5 million units at a price range of $6 to

Agora, a Chinese provider of APIs for developers to embed voice, video, and messaging, raised $350 million by offering 17.5 million ADSs at $20, above the range of $16 to $18. At pricing, the company commands a fully diluted market value of $2.2 billion. Agora plans to list on th

PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, raised $60 million by offering 3.8 million shares at $16, within the range of $15 to $17. The company offered 625,000 more shares than anticipated. Insiders indicated on $27 million

Ebang International Holdings, which makes equipment for cryptocurrency mining in China, raised $101 million by offering 19.3 million shares at $5.23, slightly below the midpoint of the range of $4.50 to $6.50. The company offered 59,000 fewer shares than anticipated. At pricing,

Fusion Pharmaceuticals, a Phase 1 biotech developing radiopharmaceuticals for solid tumors, raised $213 million by offering 12.5 million shares at $17, above the range of $14 to $16. The company originally filed to offer 8.4 million shares at the same range before increasing the

Kensington Capital Acquisition, a blank check company targeting the automotive industry, raised $200 million by offering 20 million units at $10 in its initial public offering. The company originally planned to offer raise $175 million by offering 17.5 million units. Each un

Fusion Acquisition, a blank check company targeting the financial services industry, raised $305 million by offering 30.5 million units at $10. The company originally filed to raise $250 million before increasing its proposed offering to $300 million earlier on Thursday. Each un

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, raised $213 million by offering 12.5 million shares at $17, above the original range of $14 to $16, and in line with the upwardly-revised share offering and price it filed on Thursday morning. At the

Albertsons Companies, a US grocer operating under Albertsons, Safeway, and other banners, raised $800 million by offering 50 million shares at $16, below the range of $18 to $20. The entire deal was sold by existing shareholders, who had originally planned to sell 65.8 million s

The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70% of the year's healt

Lemonade (LMND) launched its IPO on Thursday, in a deal set to raise $270 million next week by offering shares at a range of $23 to $26. Baillie Gifford plans to take down $100 million of the IPO (37%). At the $24.50 midpoint, the New York insurer would be valued at about $1.4 bi

Artius Acquisition, a blank check company formed by industry veterans targeting the tech sector, filed on Thursday with the SEC to raise up to $525 million in an initial public offering. The New York, NY-based company plans to raise $525 million by offering 52.5 million units at

Fusion Acquisition, a blank check company targeting the financial services industry, increased the proposed unit offering for its upcoming IPO on Thursday. The New York, NY-based company now plans to raise $300 million by offering 30 million units at $10. The company had previous

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, raised the proposed deal size for its upcoming IPO on Thursday. The Boston, MA-based company now plans to raise $213 million by offering 12.5 million shares at an assumed offer price of $17. The comp

Lemonade, which provides online self-serve renters and homeowners insurance, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $270 million by offering 11 million shares at a price range of $23 to $26. At the midpoint of the proposed range, Le

Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering in the US. The pre-revenue company is currently listed in London on the AIM under the ticker RENX; it cl